S&N CEO O’Donnell Exhorts UK Health Committee On Merits Of Innovation
This article was originally published in The Gray Sheet
Executive Summary
Smith & Nephew's Versajet exemplifies an innovative treatment that is cost-effective in the long-term despite higher initial costs, the firm says